Ron Bentsur, Chairman & CEO at Nuvectis Pharma, Inc. (NVCT), bought 20,000 shares at $4.92 ($98K) on 2024-11-15, disclosed to the SEC on 2024-11-18.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| NVCT | BUY | 2024-12-26 | $21K | — | Filing → |
| NVCT | BUY | 2024-05-15 | $13K | — | Filing → |
| NVCT | BUY | 2024-05-13 | $13K | — | Filing → |